medigraphic.com

2020, Number 1

<< Back Next >>

Rev Fac Med UNAM 2020; 63 (1)

Usefulness of Positron Emission Tomography/ Computed Tomography (PET/CT) in Patients Diagnosed with Medulloblastoma

García DRE, Díaz BS, Villanueva RR, López LR, Valencia VJL, Rivera-Bravo B

Language: Spanish
References: 27
Page: 34-41
PDF size: 319.57 Kb.


ABSTRACT

PET/CT (positron emission tomography/computed tomography, for its acronym in English) is a unique imaging method that provides in vivo evidence of both biochemical and physiological activities of the brain, spinal cord and tumors that involve these structures. Medulloblastoma is the most common malignant tumor of the central nervous system (CNS) in pediatric patients, so PET/CT plays an important role as it provides information on the grade and extent of the tumor, as well as to determine the appropriate site for the biopsy, assessing the response to the treatment and the patient’s prognosis.
There are different radiopharmaceuticals for the evaluation of central nervous system tumors, but 18F FDG (Fluor-2-fluoro- 2-desoxy-D-glucose) and 68Ga-DOTA-NOC (68Ga-DOTA0- 1NaI3-octreotide) have been studied to help us evaluate and follow up patients diagnosed with medulloblastoma. Medulloblastoma has an overexpression of glucose transporters, mainly type 1, and an overexpression of predominantly type 2 somatostatin receptors, which allows a high affinity for these radiopharmaceuticals.


REFERENCES

  1. Rivera-luna R, Niembro-zúñiga AM, Zarco A, Marhxbracho a. Meduloblastoma en pediatría. Pronóstico y tratamiento en la actualidad. 2007;143(5):415-20.

  2. Alegría-Loyola MA, Andrés Galnares-Olalde J. Tumores del sistema nervioso central* Tumors of the central nervous system. 2017;55.

  3. Sinning M. Clasificación De los Tumores Cerebrales. Rev Médica Clínica Las Condes [Internet]. 2017;28(3):339-42. Disponible en: http://linkinghub.elsevier.com/retrieve/pii/ S0716864017300597

  4. Martínez León MI. Meduloblastoma pediátrico, revisión y puesta al día. Radiología. 2010;53(2):134-45.

  5. Packer RJ, Vezina G. Management of and prognosis with medulloblastoma: therapy at a crossroads. Arch Neurol. 2008;65:1419-24.

  6. Zukotynski K, Fahey F, Kocak M, Kun L, Boyett J, Fouladi M, et al. 18F-FDG PET and MR imaging associations across a spectrum of pediatric brain tumors: a report from the pediatric brain tumor consortium. J Nucl Med. 2014;55(9):1473-80. https://doi. org/10.2967/ jnumed.114.139626.

  7. Gururangan S, Hwang E, Herendon JE II, Fuchs H, George T, Coleman RE. [18F] fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma. Neurosurgery. 2004;55: 1280-8.

  8. Yüksel M, Lutterbey G, Biersack HJ, Elke U, Hasan C, Gao Z, et al. 111In-pentetreotide scintigraphy in medulloblastoma: a comparison with magnetic resonance imaging. Acta Oncol. 2007;46(1):111-7.

  9. Vaidyanathan G, Affleck DJ, Zhao XG, Keir ST, Zalutsky MR. [177Lu]-DOTAO-Tyr3-octreotate: a potential targeted radiotherapeutic for the treatment of medulloblastoma. Curr Radiopharm. 2010;3:29-36.

  10. Rodríguez-Carbajal J. Neuroimagen funcional. Combinación de anatomía y fisiología: I. Introducción. Gac Med Mex. 2002;138(3):247-8.

  11. Sharma A, McConathy J. Overview of PET tracers for brain tumor imaging. PET Clin [Internet]. Elsevier Inc; 2013;8(2):129-46. Disponible en: http://dx.doi.org/10.1016/j. cpet.2013.02.001

  12. Thust SC, van den Bent MJ, Smits M. Pseudoprogression of brain tumors. J Magn Reson Imaging. 2018;48(3):571-89. doi:10.1002/jmri.26171.

  13. Chang SM, Van den Bent MJ, Macdonald DR, Vogelbaum MA, Lee EQ, Wen PY. Response Assessment in Neuro-Oncology Clinical Trials. J Clin Oncol. 2017;35(21):2439-49. doi:10.1200/jco.2017.72.7511.

  14. Dunet V, Prior JO. FET PET in neuro-oncology and in evaluation of treatment response. PET Clin. 2013;8(2):147- 62. doi:10.1016/j.cpet.2012.09.005.

  15. Suárez Fernández JP, Maldonado Suárez A, Domínguez Grande ML, Serna Macías JA, Kostvinseva O, Ordovás Oromendía A, et al. La Tomografía por Emisión de Positrones (PET) en la práctica clínica oncológica. Oncol [Internet]. 2004;27(8):479-89. Disponible en: http:// scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0378- 48352004000800002&lng=en&nrm=iso&tlng=en

  16. Estela Herrera-González N, Martínez-García F, Mejía- Jiménez E, Estela N, González H. El efecto Warburg: la mano derecha en el desarrollo del cáncer. Rev Esp Méd Quir [Internet]. 2015;20:171-7. Disponible en: http://www. medigraphic.com/pdfs/quirurgicas/rmq-2015/rmq152h.pdf

  17. Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, et al. Response assessment in neuro-oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncology. 2016;18:1199-208.

  18. Reichlin S. Somatostatin. N Engl J Med. 1983; 309:1495- 1501

  19. Epelbaum J, Dournaud P, Fodor M, Viollet C: The neurobiology of somatostatin. Crit Rev Neurobiol. 1994;8: 25-44.

  20. Dutour A, Kumar U, Panetta R, et al. Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer. 1998;76:620-7.

  21. Frühwald MC, Rickert CH, O’Dorisio MS, et al. Somatostatin receptor subtype 2 is expressed by supratentorial primitive neuroectodermal tumors of childhood and can be targeted for somatostatin receptor imaging. Clin Cancer Res 2004; 10:2997-3006.

  22. Reubi JC, Lang W, Maurer R, Koper JW, Lamberts SWJ. Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system. Cancer Res. 1987;47:5758-64.

  23. Cervera P, Videau C, Viollet C, Petrucci C, Lacombe J, Winsky-Sommerer R, et al. Comparison of somatostatin receptor expression in human gliomas and medulloblastomas. J Neuroendocrinol. 2002 Jun;14(6):458-71.

  24. Müller HL, Frühwald MC, Scheubeck M, Rendl J, Warmuth- Metz M, Sörensen N, et al. Posible papel de la gammagrafía con receptores de somatostatina en el diagnóstico y seguimiento de niños con meduloblastoma. J Neurooncol. 1998 May;38(1):27-40.

  25. Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003; 30:1338-47.

  26. Virgolini I, Ambrosini V, Bomanji JB, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA- conjugated peptides: 68Ga-DOTATOC, 68Ga-DOTANOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004-2010.

  27. Weinstock JV, Elliott D. The somatostatin immunoregulatory circuit present at sites of chronic inflammation. Eur J Endocrinol. 2000;143:S15-S19.




2020     |     www.medigraphic.com